![IconGems-Print](images/IconGems-Print.png)
243 – Contributed Poster Presentations: Biopharmaceutical Section
Escalation with Overdose Control for Drug Combination Using Time to Toxicity Data in Cancer Phase I Trials
Marcio A. Diniz
Cedars-Sinai Medical Center
José L. Jimenez
Politecnico di Torino
Mourad Tighiouart
Cedars-Sinai Medical Center
Bayesian adaptive methods for phase I trials such as the continual reassessment method (CRM) and escalation with overdose control (EWOC) do not take into account the time for a patient exhibits dose limiting toxicity (DLT), since the toxicity outcome is treated as a binary variable. This characteristic is proven to increase the study duration and makes it almost non-feasible in practice. Despite there are several methodologies to overcome this limitation in single agent trials, there only a few approaches specifically designed for drug combinations that model the time to toxicity. In this paper, we propose a Bayesian adaptive EWOC design that incorporates both the status of DLT and the time to toxicity using a cure rate model in clinical trials with drug combinations.